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TGF-b-activating kinase-1 inhibits cell cycle and expression of tial fibrotic changes in an animal model of unilateral
cyclin D1 and A in LLC-PK1 cells. ureteral obstruction [1, 2]. The growth of proximal tubule
Background. Transforming growth factor-b (TGF-b) is known epithelial cells occurs during physiological processes suchto play an important role in the pathophysiology of renal tubu-
as renal development and pathophysiological processeslar disease. Researchers have recently identified a novel mito-
such as repair of damage to the tubular epithelium [1, 3,gen-activated protein kinase kinase kinase (MAPKKK), TAK
(TGF-b activated kinase)1, which stimulates the MKK3/6-p38K 4]. Recently, transgenic mice overexpressing constitutive
pathway. The purpose of our study was to investigate the func- active TGF-b showed that renal expression of the
tional role of the TAK1-MKK3/6-p38K pathway and classical
transgene was localized to the proximal tubule epithe-MAPK cascades in the progression of the cell cycle in renal
lium [5]. The kidneys of these transgenic mice showedtubular cells.
Methods. The constitutive active form and negative form of dilatation of the proximal tubules and flattened atrophic
TAK1 (TAK1dN and TAK1K63W, respectively), and active changes of tubular epithelial cells [5]. An understanding
and negative forms of the p42/44 MAPK-activator, MKK1 of the signal transduction mechanisms by which TGF-b(S222E and S222A, respectively) were transfected to LLC-PK1
exerts its pathophysiological roles is essential for furthercells. Western blot analyses and promoter-luciferase assay of
understanding the control of growth of renal proximalcyclins D1, D2, D3, E, and A were performed, and cell cycle
progression was analyzed by FACS scan. tubular cells and its pathogenesis in renal tubular dis-
Results. TAK1dN stimulated MKK6 and p38K activity and eases.
inhibited the percentage of the S and G2/M phases. TAK1K63
LLC-PK1 cells are a permanent, well-characterized,W inhibited TGF-b-stimulated MKK6 and p38K activity.
porcine renal proximal tubular cell line that also expressCyclin D1 and cyclin A protein levels and promoter activities
were negatively regulated by TAK1dN. In contrast, overex- some characteristics of cells from the distal nephron.
pression of the active form of p42/44 MAPK-activator, MKK1, Since cultured cells are needed for any precise analysis
increased cyclin D1 and A promoter activity and protein levels. of the mechanisms of gene transcription and promoter
Conclusion. The growth-inhibitory effects of TGF-b are at
assay, we decided to use this cell line to investigate theleast partially mediated by the TAK1-MKK6-p38K pathway.
signal transduction mechanisms by which TGF-b exertsCyclin D1 and A promoter activity and cell cycle progression
in renal tubular cells are negatively regulated by the TAK1- its roles in cell cycle progression.
MKK6-p38K pathway and positively regulated by the MKK1- Mitogen-activated protein kinases (MAPK) have been
p42/44MAPK pathway. shown to play an important role in transducing extracel-
lular signals into cellular response [6–8]. The classical
MAPK pathway (simply called MAPK here, also known
Transforming growth factor-b (TGF-b) plays an im-
as ERK) is commonly activated by growth factors andportant role in the pathophysiology of renal tubular dis-
has been shown to play a crucial role in cell proliferationeases [1, 2]. In diabetes mellitus, TGF-b has been impli-
and early development [6, 8, 9].cated in renal tubular hypertrophy. TGF-b has also been
Researchers have recently identified a novel MAPKshown to be a major factor associated with tubulointersti-
kinase kinase (MAPKKK) and designated it as TAK1
(TGF-b-activating kinase 1) [10–12]. TAK1 is reported
Key words: MAP kinase, p38 kinase, renal tubule, cell cycle. to participate in the signal transduction of TGF-b and
phosphorylate the p38 kinase (p38K) and/or Jun kinase
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tion of pRb phosphorylation and blockage of the cell 50 mg/ml streptomycin, and 10% heat-inactivated fetal
calf serum (FCS; Gibco). Cells were cultured at 378C incycle at the G1/S phase [14, 15]. Although the mecha-
nisms of TGF-b-induced cell cycle inhibition have been 5% CO2.
reported to involve inhibition of the synthesis of CDK4,
Expression vectors and reporter constructsinduction of p15INK4b and p21WAF1/Cip1, and protein accumu-
lation of p27KIP1, the signal seems to be complex and Wild-type, constitutive active (TAK1dN), and consti-
tutive negative (TAK1K63W) forms of human TAK1regulated precisely and differently in each organ or cell
type [16–20]. The participation of the TAK1-MKK3/ cDNAs were generous gift of Drs. K. Matsumoto and E.
Nishida [12]. Dominant-active human MKK6 [MKK6(Glu)],6(p38 kinase kinase)-p38K pathway in TGF-b-induced
antiproliferative effects has not been evaluated. dominant-negative human MKK6 [MKK6(Ala)], wild-
type human p38K [p38K(TGY)], and dominant-nega-Mitogenic factors have been reported to stimulate the
MKK1(p42/44MAP kinase kinase)-p42/44MAPK-path- tive human p38K [p38K(AGF)] were generous gifts of
Dr. R.J. Davis [23]. Wild-type, dominant-active MKK1way and cell cycle progression [6–9]. The mechanism of
induction of cell cycle regulatory-genes by this kinase [MKK1S222E], Dominant-negative MKK1 [MKK1S222A]
human cNDAs were generous gifts of Dr. E.G., Krebscascade is not fully understood. Recently, Lavoie et al
reported a significant inhibition of mitogen-induced cyclin [8]. The cyclin D1 reporter construct used for luciferase
assays contained human cyclin D1 promoter from resi-D1 expression in CCL39 cells expressing high levels of
MKK3 together with p38K [21]. In the same study, they dues 2944 to 1139 cloned upstream of the luciferase
gene (generous gift of Dr. M. Eilers) [24]. The cyclin Ademonstrated that inhibition of p38K activity with the
specific inhibitor, SB203580, enhanced cyclin D1 tran- reporter construct used for luciferase assays contained
human cyclin A promoter from residues 2924 to 1245scription and its protein levels, and that overexpression
of constitutively active MKK1 increased cyclin D1 ex- cloned upstream of the luciferase gene (generous gift
of Dr. J. Sobczak-Thepot) [25]. The pCH110 reporterpression [21]. However, they did not test whether these
kinases control the expression of other cyclins that regu- construct contains the SV40 promoter upstream of the
b-galactosidase gene (Pharmacia Biotechnology Inc.,late G1/S transition such as cyclin A, or if the activation
of these kinases really regulates cell cycle progression Uppsala, Sweden) [26].
[21]. In view of the importance of the TGF-b pathway
Transient transfection and luciferase assayin the pathogenesis of renal tubular disorders, we fo-
cussed on how the G1/S-phase-cyclin gene expression LLC-PK1 cells were transfected by the electroporation
method. Data are representative of at least four indepen-and cell cycle progression are controlled by two kinase
pathways in LLC-PK1 cells. dent experiments performed in duplicate and are ex-
pressed as “N-fold increase in luciferase activity” calcu-The purpose of our study was to investigate the func-
tional role of the TAK1-MKK3/6-p38K pathway and lated relative to the indicated level of cyclin D1 or A
promoter activity. Plasmids DNA (5 mg) were trans-classical MAPK cascades in cell cycle progression in the
LLC-PK1 cells, renal tubular cell line, especially in tran- fected by electroporesis. For experiments performed in
exponentially growing cells, luciferase activity was mea-scriptional regulation of the cyclin D1, cyclin A, and
cyclin E genes. We examined how G1/S-phase-cyclin sured 48 hours after transfection. Normalization was
achieved by cotransfecting 0.1 mg of pCH110, a b-galac-gene expression and cell cycle progression are regulated
when each kinase cascade is switched on and off using tosidase reporter construct, as an internal control for
the transfection efficiency. For mitogen-stimulated cyclinconstitutive active or negative mutants.
D1-luciferase reporter expression, one day following the
transfection, cells were serum-starved for 30 hours and
METHODS
then stimulated with 10% FCS for 18 hours. Luciferase
Materials and b-galactosidase activities were measured according
to the Promega (Madison, WI, USA) protocol.The specific p38K inhibitor SB203580 was provided
by SmithKline Beecham Pharmaceutical (King of Prus-
Western blot analysissia, PA, USA) [22]. The specific MKK1 inhibitor
PD98059 was purchased from Gibco (Eggenstein, Ger- Cells were lyzed in sodium dodecyl sulfate (SDS) sam-
ple buffer (50 mm Hepes pH 7.5, 150 mm NaCl, 1.5 mmmany).
MgCl2, 1 mm egtazic acid (EGTA), 10% glycerol, 1%
Cell culture and preparation of extracts Triton X-100, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mm
phenylmethylsulfonyl fluoride (PMSF), 0.1 mm sodiumLLC-PK1 cells, originally purchased from the Ameri-
can Type Culture Collection (Rockville, MD, USA), orthovanadate) at 48C. After incubation for five minutes,
lysates were centrifuged at 48C for 15 minutes at 10,000were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 50 IU/ml penicillin, g. The soluble lysates were mixed 1:4 with 5 3 Laemmli
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buffer and heated for five minutes at 958C. Soluble ly- Coulter EPICS 753 flow cytometer, and the percentages
of the cells in the G1, S, and G2/M phases were deter-sates (30 mg) were loaded per lane and separated by
SDS-PAGE using 5 and 20% acrylamide for stacking mined [27]. All experiments were repeated at least four
times.and resolving gels, respectively. Protein was transferred
to nitrocellulose (pore size 0.45 mm; Schleicher and
p38K assay and JNK assaySchuell, Keene, NH, USA) and probed with polyclonal
antibodies against cyclin D1, cyclin D2, cyclin D3, cyclin p38K assay and JNK assay were performed by immu-
noprecipitation followed by Western blot with phospho-A, and cyclin E (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or with phospho-specific antibodies against specific antibodies against phosphorylated-p38K or -JNK
(New England Biolabs). Cells were lyzed into a totalMKK3/6 (New England Biolabs, Beverly, MA, USA).
For the detection of cyclin D1 and cyclin E, the primary volume of 1.0 ml of lysis buffer containing 10 mm
b-glycerophosphate, pH 7.4, 1.0 mm ethylenediaminetet-antibodies (diluted 1/2500) and a second antibody, horse-
radish peroxidase (HRP)-conjugated goat antirabbit IgG raacetate acid (EDTA), 5.0 mm EGTA, 0.15 mm Na3VO4,
2.0 mm dithiothreitol (DTT), 20 mm HEPES, pH 7.4,(diluted 1/2500), were used. The bands were visualized
by the Amersham ECL system with 5 to 10 minute expo- 0.5% (vol/vol) Nonidet P-40, 0.1% (wt/vol), sodium
deoxycholate, 1 mm PMSF, 10 mg/ml aprotinin, and 10sure (Amersham Corp., Arlington Heights, IL, USA)
after extensive washing of the membranes. For the detec- mg/ml leupeptin. Lysates were allowed to remain on ice
for 30 minutes and then centrifuged at 15,000 3 g fortion of cyclin D2, D3, and cyclin A, the primary antibod-
ies (diluted 1/1000) and a second antibody, HRP-conju- 30 minutes at 48C. Supernatants were incubated for two
hours at 48C with 3 ml of rabbit antip38K or anti-JNKgated goat antirabbit IgG (diluted 1/2500), were used.
The bands were visualized by the Amersham ECL sys- antibody and protein A-Sepharose. Immune complexes
were recovered by centrifugation and the immune com-tem with 10 to 30 minute exposure after extensive wash-
ing of the membranes. We performed densitometric plexes were electrophoresed using 5/20% gradient SDS-
analysis of the band intensity of Western blot analysis. PAGE gel. The protein was transferred to nitrocellulose,
We summarized the Western blot data on transfected probed with polyclonal antibodies with phospho-specific
cells in comparison with data on control cells. ECL films antibodies against phosphorylated-p38K or -JNK, and
were scanned using an Epson scanner (Nagano, Japan). visualized by the Amersham ECL system after extensive
Signals on Western blots were quantitated by densitome- washing of the membranes.
try using an image analysis software application (NIH
StatisticsImage 1.47). Equal loading among lanes was confirmed
by scanning and densitometry of identical SDS-PAGE The results were given as means 6 sem. The differ-
gels run in parallel to the gels for immunoblots and ences were tested using analysis of variance. P , 0.05
stained with Coomassie blue. was considered significant.
[3H]-thymidine incorporation
RESULTSLLC-PK1 cells were plated in 24-well plates after
Activation of TAK1 pathway decreased and MKK1transfection and incubated in a medium containing
pathway increased in [3H]-thymidine incorporation in0.25%-FCS in the presence or absence of TGF-b (Pep-
LLC-PK1 cells.tide Institute, Osaka Japan) for 20 hours. For the last four
We first examined the effects of the TAK1 pathwayhours, the cells were pulsed with 1 mCi [3H]-thymidine
and MKK1 pathway on cell proliferation of LLC-PK1(Amersham). After the cells were washed three times
cells by [3H]-thymidine uptake. Figure 1A shows thein ice-cold PBS, they were precipitated two times with
effects of the TAK1 pathway on [3H]-thymidine uptake.10% trichloroacetic acid (TCA), redissolved in 0.5 m
The cells were transfected with indicated vectors andNaOH, and counted in an Aquasol-2 scintillation cock-
incubated with DMEM medium containing 10% FCStail (NEN Research Products, Boston, MA, USA).
with or without TGF-b for 12 hours. TGF-b treatment
Cell cycle analysis by flow cytometry inhibited the [3H]-thymidine uptake to 56.4% in LLC-
PK1 cells. Transfection of TAK1dN inhibited the [3H]-LLC-PK1 cells were cultured in a 75 cm2 flask. The
thymidine uptake to 31.3% in the presence of TGF-b.cells were incubated in a medium plus 10% FCS for 24
Transfection of TAK1 inhibited [3H]-thymidine uptakehours after transfection of TAK1dN or control vector.
slightly but not significantly. Surprisingly, transfection ofThe samples were washed twice with PBS and then resus-
TAK1dN inhibited [3H]-thymidine uptake to 44.5% evenpended in 70% ethanol for at least 12 hours at 48C. Fixed
in the absence of TGF-b. This inhibition by TAK1dNand permeabilized cells were collected by centrifugation
was recovered by p38K inhibitor SB203580 (10 mm).and washed with PBS. The cells were stained with pro-
pidium iodide and analyzed by flow cytometry using a Transfection of TAK1K63 W plasmid significantly abol-
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Fig. 1. Effect of the TAK1 pathway and MKK1 pathway on [3H]-thymidine incorporation in LLC-PK1 cells. (A) Cells were transfected with
plasmids containing TAK1, TAK1dN, TAK1K63W, or pNK11 (vector) and incubated with DMEM medium containing 10% FCS in the presence
or absence of TGF-b (20 ng/ml) for 24 hours. [3H]-thymidine incorporation was measured during the last 4 hours. SB203580 (10 mm; a p38K
inhibitor) was added just after the transfection of TAK1dN plasmid. Results are means 6 sem of five or six independent experiments. Symbols
are: (h) TGF-b; ( ) control; *P , 0.05; #P , 0.01. (B) The cells were transfected with wild type MKK1, MKK1(S222A), MKK1(S222E), or
pCDNA3 (vector) and incubated with DMEM medium without FCS. PD98059 (100 mm; MKK1 inhibitor) was added just after the transfection
of MKK1 (S222E). Results are the means 6 sem of five or six independent experiments (*P , 0.05; #P , 0.01; NS is not significant).
ished the growth-inhibitory effects of TGF-b. The depic- in LLC-PK1 cells is negatively regulated by the TAK1
pathway and positively regulated by the MKK1-MAPKtion of the TAK1 pathway in Figure 1A suggests that
(1) TGF-b significantly inhibited proliferation in the pathway. However, since the efficiency of transfection
is over 95% cells in our experimental systems (data notpresence of TAK1K63W, and (2) TAK1K63W signifi-
cantly abolished the TGF-b-induced inhibitory effects shown), the physiological response may or may not be
real, as our overexpression data suggests.of thymidine incorporation. We suspect that the TAK1
pathway partially mediates the growth-inhibitory path-
Activation of the TAK1 pathway induced decreases inway of TGF-b, and that other pathways such as Smad
the expression of cyclin D1 and cyclin A protein, butor cell cycle inhibitors (p15INK4, p27Kip1) may be involved
not other cyclinsin the growth-inhibitory mechanisms of TGF-b.
In contrast, the constitutive active form of MKK1 To further examine the mechanisms of the inhibitory
effects of the TAK1 pathway on cell proliferation in(S222E), the activator of classical MAP kinase, increased
[3H]-thymidine uptake to 258% (Fig. 1B). [3H]-thymidine LLC-PK1 cells, the effects of the activation of the TAK1
pathway on protein expression of G1/S phase cyclinsuptake in LLC-PK1 cells was not significantly changed
by wild type-MKK1 or by constitutive negative MKK1 such as cyclins D1, D2, D3, E, and A were studied. The
protein levels of cyclin D1 and cyclin A significantly(S222A). These results suggested that cell proliferation
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decreased in cells expressing TAK1dN construct when
compared with control cells transfected with the corre-
sponding empty vector (Fig. 2 A, E). On the other hand,
transfection of TAK1dN did not change cyclin D2, D3,
and E protein levels in our experimental condition (Fig.
2 B, C, D).
The MKK6-p38K pathway is involved in the inhibitory
effect of TAK1 on cyclin D1 expression
To investigate the downstream signaling of TAK1,
we performed immunoblot analysis for phospho-specific
MKK3/6, p38K, and JNK. As shown in Figure 3 A and
B, phosphorylation of MKK3/6 and p38K was stimulated
by overexpression of wild-type TAK1 and TAK1dN.
This increment of TAK1dN-induced p38K-phosphoryla-
tion was inhibited in the presence of SB203580 (10 mm;
Fig. 3B). On the other hand, JNK phosphorylation was
not changed in our experimental conditions (Fig. 3C).
The protein level of cyclin D1 was increased when
TAK1K63W was expressed (Fig. 3D). Figure 3D demon-
strated that cyclin D1 protein expression was inhibited
much more weakly by overexpression of TAK1 than
TAK1dN.
To investigate the role of the TAK1 signaling pathway
in the regulation of cyclin D1 and cyclin A expression
more directly, we used previously reported constructs
containing cyclin D1 and cyclin A promoter fragments
fused to the luciferase reporter gene.
LLC-PK1 cells transiently transfected with cyclin D1-
luciferase reporter gene responded to TGF-b with a
68.2% decrease in reporter gene activity (Fig. 4A). Since
overexpression of TAK1K63W totally abolished the
TGF-b-dependent decrease in cyclin D1-luciferase activ-
ity, this down-regulation of cyclin D1 reporter activity
in TGF-b-treated cells probably resulted from an activa-
tion of the TAK1 pathway. Cyclin D1-luciferase activity
was inhibited by overexpression of TAK1dN to almost
the same extent that it was inhibited by TGF-b. This
dramatic down-regulation of the cyclin D1 reporter activ-
ity was also probably transduced by the p38K pathway,
since p38K-specific inhibitor SB203580 abolished the in-
hibitory effects of TAK1dN on cyclin D1-luciferase activity.
Amersham ECL system with 5 to 10 minutes of exposure. For theFig. 2. Effects of TAK1 activation on protein expression of cyclins D1,
detection of cyclins D2, D3, and A, the primary antibodies (dilutedD2, D3, E, and A. Immunoblots of cyclin D1 (A), cyclin D2 (B), cyclin
1/1000) and a second antibody, HRP-conjugated goat antirabbit IgGD3 (C), cyclin E (D), and cyclin A (E) were performed using whole
(diluted 1/2500), were used. The bands were visualized by the Amers-cell lysates of LLC-PK1 cells. Exponentially growing cells were trans-
ham ECL system with 10 to 30 minutes of exposure after extensivefected with TAK1dN or empty vector (pNK11) and incubated with
washing of the membranes. Immunoblots of cyclins D1, D2, D3, E,DMEM medium containing 10% FCS. Whole cell lysates were sepa-
and A were performed at least five times. Values were obtained byrated by SDS-PAGE gels. Cyclin D1, D2, D3, E, and A protein levels
densitometry of immunoblots of cyclin D1 (A), cyclin D2 (B), cyclinwere detected by Western blot analysis. For the detection of cyclin D1
D3 (C), cyclin E (D), and cyclin A (E), and expression is presented asand cyclin E, the primary antibodies (diluted 1/2500) and a second
fraction of expression in control (pNK11). Results are the means 6antibody, horseradish peroxidase (HRP)-conjugated goat antirabbit
sem of five independent experiments (*P , 0.05).IgG (diluted 1/2500), were used. The bands were visualized by the
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Fig. 3. Involvement of the MKK3/6-p38K in TAK1 pathway in LLC-PK1 cells. (A) Cells were transfected with plasmids containing wild TAK1,
TAK1dN, TAK1K63W, or pNK11 (vector) and incubated with DMEM medium containing 10% FCS in the absence of TGF-b for 24 hours.
SB203580 (10 mm; p38K inhibitor) was added just after the transfection of TAK1dN. Immunoblots of phospho-specific MKK3/6 (A) and cyclin
D1 (D) were performed using whole cell lysates of LLC-PK1 cells. As described in the methods section, phosphorylation of p38K (B) and JNK
(C) was detected by immunoprecipitation using p38K and JNK antibodies followed by immunoblots with phospho-specific p38K and JNK antibodies.
For the detection of cyclin D1, phospho-specific MKK3/6, p38K, and JNK, primary antibodies (diluted 1/2500) and a second antibody, horseradish
peroxidase (HRP)-conjugated goat antirabbit IgG (diluted 1/2500), were used. The bands were visualized by the Amersham ECL system with 5
to 10 minute exposure. For the detection of phospho-specific MKK3/6, p38K, and JNK, the primary antibodies (diluted 1/1500) and a second
antibody, HRP-conjugated goat antirabbit IgG (diluted 1/2500), were used. The bands were visualized by the Amersham ECL system with 10 to
30 minutes of exposure after extensive washing of the membranes. Immunoblots of cyclin D1. Values were obtained by densitometry of immunoblots
of phospho-specific MKK3/6 (A), phospho-specific p38K (B), phospho-specific JNK (C), and cyclin D1 (D), and expression is presented as fraction
of expression in control (pNK11). Results are means 6 sem of five independent experiments (*P , 0.05).
We also observed that TAK1 slightly inhibited cyclin D1 or p38K (AGF) ameliorated the inhibitory effects of
TAK1dN on cyclin D1 promoter activity (Fig. 4B). Par-promoter activity, though not to a statistically significant
extent (Fig. 4A). tial inhibition on cyclin D1 promoter activity was ob-
served in cells transfected with MKK6 (Glu) and p38KWe next examined whether the MKK3/6-p38K path-
way is essential for TAK1-dependent regulation of cyclin (TGY) in the absence of TAK1dN. These data suggested
that the inhibitory effect of TAK1 to cyclin D1 promoterD1 promoter activity. To test this hypothesis, we cotrans-
fected constitutive active and negative mutant plasmids activity is transduced by the MKK6-p38K pathway.
of TAK1 and MKK6, and wild type and constitutive
The MKK6-p38K pathway is involved in the inhibitorynegative mutant plasmids of p38K with cyclin D1 pro-
effect of TAK1 on cyclin A expressionmoter-luciferase plasmid. The most significant inhibition
of cyclin D1 promoter activity was observed in cells trans- LLC-PK1 cells transiently transfected with cyclin A-
luciferase reporter gene responded to TGF-b with afected with TAK1dN, MKK6 (Glu), and p38K (TGY,
wild type). In contrast, cotransfection of MKK6 (Ala) 76.2% decrease in reporter gene activity (Fig. 5A). Since
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Fig. 4. Involvement of the TAK1-MKK6-p38K path-
way in cyclin D1 promoter activity and protein expres-
sion in LLC-PK1 cells. (A) Cells were transfected with
plasmids containing TAK1, TAK1dN, TAK1K63W, or
pNK11 (vector) and incubated with DMEM containing
10% FCS in the presence (h) or absence ( ) of TGF-b
(20 ng/ml) for 24 hours. LLC-PK1 cells were cotrans-
fected with cyclin D1 promoter-luciferase construct
and b-galactosidase reporter construct. SB203580 (10
mm) was added just after the transfection of TAK1dN.
Luciferase enzyme units were normalized to b-galac-
tosidase. The N-fold increase in luciferase activity was
calculated relative to the basal level of cyclin D1-luci-
ferase transfected with the empty vector. Results are
means 6 sem of five or six independent experiments
(*P , 0.05; #P , 0.01). (B) After cotransfecting the
LLC-PK1 cells with cyclin D1 promoter-luciferase con-
struct, b-galactosidase reporter construct, and expres-
sion vectors containing TAK1, MKK6, and p38K con-
structs, they were incubated with DMEM medium
containing 10% FCS in the absence of TGF-b for 24
hours. The N-fold increase in luciferase activity was
calculated relative to the level of cyclin D1-luciferase
activity transfected with TAK1dN, MKK6(Glu), and
p38K. Results are means 6 sem of four or six indepen-
dent experiments. (#P , 0.01).
overexpression of TAK1K63W at least partially abol- SB203580 also abolished the inhibitory effects of
TAK1dN on cyclin A-luciferase expression. We furtherished the TGF-b-dependent decrease in cyclin A-lucifer-
ase activity, this down-regulation of cyclin A reporter examined the regulation of cyclin A protein expression
when these TAK1 mutants were transfected. Whenexpression in TGF-b-treated cells also probably resulted
from an activation of the TAK1 pathway. Overexpres- TAK1K63W was transfected, a significantly higher level
of cyclin A expression could be detected compared tosion of TAK1dN inhibited cyclin A-luciferase activity.
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either the empty vector or the wild-type TAK1 (Fig.
5B). Conversely, the protein levels of cyclin A were
significantly reduced in TAK1dN-expressing cells (Fig.
5B). We also observed that TAK1 slightly inhibited
cyclin A promoter activity, though not to a statistically
significant extent (Fig. 5A).
We next cotransfected constitutive active and negative
mutant plasmids of TAK1, MKK6, and p38K with cyclin
A promoter-luciferase plasmid. The most significant in-
hibition of cyclin A promoter activity was observed in
cells transfected with TAK1dN, MKK6 (Glu), and p38K
(TGY, wild type). In contrast, cotransfection of MKK6
(Ala) or p38K (AGF) ameliorated the inhibitory effects
of TAK1dN on cyclin A promoter activity (Fig. 5C).
These data suggested that the inhibitory effect of TAK1
on cyclin A promoter activity is also transduced by the
MKK6-p38K pathway.
MKK1-p44/p42 MAPK pathway stimulates cyclin A-
and cyclin D1-promoter activity
We next examined the role of the MKK1-p44/
p42MAPK signaling pathway in the regulation of cyclin
A and cyclin D1 promoter activity and protein expres-
sion. We performed a transient transfection with an
empty vector (pCDNA3) or vector containing wild type,
constitutive active MKK1(S222E), and constitutive neg-
ative MKK1(S222A) fragments together with the cyclin
Fig. 5. Involvement of the TAK1-MKK6-p38K pathway in cyclin A
promoter activity in LLC-PK1 cells. (A) Cells were cotransfected with
cyclin A promoter-luciferase construct, b-galactosidase reporter con-
struct, and expression vectors containing TAK1 constructs, TAK1,
TAK1dN, TAK1K63W, or pNK11 (vector), and they were then incu-
bated with DMEM medium containing 10% FCS in the presence (h)
or absence ( ) of TGF-b (20 ng/ml) for 24 hours. LLC-PK1 cells were
cotransfected with cyclin A promoter-luciferase construct, b-galactosi-
dase reporter construct, and expression vectors containing TAK1 con-
structs. SB203580 (10 mM) was added after the transfection of TAK1dN.
Luciferase enzyme units were normalized to b-galactosidase. The N-fold
increase in luciferase activity was calculated relative to the basal level
of cyclin A-luciferase transfected with the empty vector. Results are
means 6 sem of five or six independent experiments (*P , 0.05; #P ,
0.01). (B) Immunoblots of cyclin A were performed using whole cell
lysate of LLC-PK1 cells. For the detection of cyclin A the primary
antibodies (diluted 1/1000) and a second antibody, horseradish peroxi-
dase (HRP)-conjugated goat antirabbit IgG (diluted 1/2500), were used.
The bands were visualized by the Amersham ECL system with 10 to
30 minutes of exposure after extensive washing of the membranes.
Values were obtained by densitometry of immunoblots of cyclin cyclin A,
and expression is presented as fraction of expression in control (pNK11).
Results are means 6 sem of five independent experiments (*P , 0.05).
(C) LLC-PK1 cells were cotransfected with cyclin A promoter-luciferase
construct, b-galactosidase reporter construct, and expression vectors
containing TAK1, MKK6, p38K constructs, and they were then incu-
bated with DMEM containing 10% FCS in the absence of TGF-b for
24 h. The N-fold increase in luciferase activity was calculated relative
to the level of cyclin A-luciferase transfected with TAK1dN,
MKK6(Glu), and p38K(TGY). Results are means 6 sem of four or six
independent experiments (#P , 0.01).
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A- or cyclin D1-luciferase reporter gene and the b-galac- TGF-b has been implicated in the pathophysiology of
renal tubular disorders such as hypertrophy or fibrosistosidase expression vector.
When MKK1 (S222E) was expressed, cyclin A- and in chronic renal diseases [1, 2, 28, 29]. The growth of
proximal tubule epithelial cells occurs during renal de-cyclin D1-promoter activity increased significantly by
13.6-and 3.0-fold, respectively, in LLC-PK1 cells cultured velopment and in processes such as the repair of damage
to the tubular epithelium [1, 3, 4]. Understanding thein a DMEM medium without FCS, and this stimulation
was inhibited by MKK1 inhibitor PD98059(10 mm) (Fig. molecular mechanisms of TGF-b- and growth factor-
mediated cell cycle regulation of renal proximal tubular6 A, C). The change of the cyclin A promoter level is
increased dramatically by MKK1 or MKK1(S222E) to cells is important because this response has been known
to be involved in the progression of many renal tubular7.4 6 1.0 and 13.6 6 2.5 times the control vector, respec-
tively. These changes are very high compared with those diseases. We chose to focus on LLC-PK1 cells in this
study for the following reasons. LLC-PK1 cells are aof cyclin D1 promoter activity (2.5-and 3.0-fold increases
by MKK1 and MKK1 (S222E), respectively). The 2.1 6 permanent, well-characterized renal proximal tubular
cell line. This cell line can be used to investigate the0.7-fold change of cyclin A promoter activity by
MKK1(S222A) transfection was not statistically signifi- signal transduction mechanisms by which the TGF-b-
TAK1 pathway and MKK1-p42/44 MAPK pathway ex-cant compared with the change of the control vector.
This large biological variability of cyclin A promoter ert their roles in cell cycle progression of renal tubular
cells. A suitable stable cell line such as LLC-PK1 cellsactivity may be attributable to the very sensitive response
of the cyclin A promoter activity to MKK1 plasmid trans- is required to analyze the precise mechanisms of gene
transcription and promoter assay using transfection.fection in LLC-PK1 cells.
We further examined the regulation of cyclin A and The inhibitory effect of TGF-b on cell proliferation is
mediated at least in part by inhibition of pRb posphoryla-cyclin D1 protein expression when these MKK1 mutants
tion and blockage of the cell cycle at the G1/S phase [14, 15].were transfected. When MKK1(S222E) was transfected,
Although the mechanisms of TGF-b-induced cell cyclea higher level of cyclin A and cyclin D1 expression could
inhibition have been reported to involve suppression ofbe detected compared to either the empty vector or
CDK4 or induction of cyclin-dependent-kinase-inhibi-MKK1 (Fig. 6 B, D). Conversely, the protein levels of
tors, the inhibitory signal seems to be regulated preciselycyclin A and cyclin D1 were reduced in MKK1 (S222A)-
and differently in each organ or cell type [16–18, 20].expressing cells (Fig. 6 B, D). This result suggested that
TAK1 was originally identified as a novel MAPKKKthe MKK1-p44/42MAPK pathway positively regulated
recognized as a potential mediator of TGF-b signalcyclin A and cyclin D1 promoter activity and protein
transduction [12]. The biological function of this TAK1expression.
pathway and antiproliferative effects has not been well
Activation of the TAK1 pathway decreased the clarified. TAK1 was reported to activate at least two
percentage of cells in S and G2/M phases MAPKK-MAPK pathways, that is, the MKK3/6-p38K
pathway, and the SEK1/MKK4-SAPK/JNK pathway [10,The effects of the TAK1 pathway on cell cycle progres-
11]. Moriguchi et al reported that the activity of MKK3/6sion were examined using flow cytometry. When LLC-
and p38K is enhanced by the coexpression of activePK1 cells expressing the empty vector were incubated
TAK1 in COS7 cells [13]. On the other hand, overexpres-with 10% FCS for 24 hours, the percentage of S phase
sion of a constitutive active mutant of TAK1 resulted inand G2/M phase were increased compared to the cells
the activation of SAPK/JNK and its activator SEK1/incubated without FCS. The cells expressing constitutive
MKK4 in A673 human rhabdomyosarcoma cells [11].active TAK1dN significantly reduced the FCS-stimu-
These findings suggested that TAK1 could stimulatelated increase of the S and G2/M phases (Fig. 7). This
both MKK3/6-p38K and SEK1/MKK4-SAPK/JNK path-result confirmed the inhibitory effects of the TAK1 path-
ways. In the present study, expression of constitutiveway on cell cycle progression.
active mutant TAK1 resulted in a significant activation
of the MKK3/6 and p38K pathway. We did not observe a
DISCUSSION significant activation of SAPK/JNK in our experimental
The major findings of the present study are that the condition. These discrepancies may derive from the char-
growth inhibitory effects of TGF-b are at least partially acteristics of the cells and experimental conditions.
mediated by the TAK1-MKK6-p38K pathway, and that We also found that the overexpression of TAK1dN
this pathway negatively regulates cyclin D1 and cyclin inhibited cyclin D1 and cyclin A promoter activity and
A promoter activity and cell cycle progression in renal its protein expression, and that TAK1K63W recovered
tubular cells. On the other hand, the MKK1-p42/ TGF-b-induced inhibition of cyclin D1 and cyclin A pro-
44MAPK pathway up-regulates cyclin D1 and cyclin A moter activity. This inhibitory effect of TAK1 in cyclin
D1 and cyclin A transcription was recovered by the ex-promoter.
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Fig. 6. Stimulation of cyclin A and cyclin D1 promoter activity by the MKK1-p44/p42 MAP kinase pathway. (A) After cotransfecting the cells
with cyclin A promoter-luciferase construct, b-galactosidase reporter construct, and expression vectors containing MKK1 constructs [wild type
MKK1, MKK1(S222E), MKK1(S222A), or pCDNA3 (vector)], they were incubated with DMEM medium without FCS. PD98059 (100 mM; MKK1
inhibitor) was added just after the transfection of MKK1(S222E). Results are means 6 sem of four or five independent experiments (*P , 0.05;
#P , 0.01). (B) Whole cell lysates were separated by SDS-PAGE gels. The cyclin A protein levels were detected by Western blot analysis. For
the detection of cyclin A, the primary antibodies (diluted 1/1000) and a second antibody, horseradish peroxidase (HRP)-conjugated goat antirabbit
IgG (diluted 1/2500), were used. The bands were visualized by the Amersham ECL system with a 10 to 30 minute exposure after extensive washing
of the membranes. Values were obtained by densitometry of immunoblots of cyclin cyclin A, and expression is presented as fraction of expression
in control (pNK11). Results are means 6 sem of four independent experiments (*P , 0.05). (C) After cotransfecting the cells with cyclin
D1 promoter-luciferase construct, b-galactosidase reporter construct, and expression vectors containing MKK1 constructs [wild type MKK1,
MKK1(S222E), MKK1(S222A), or pCDNA3 (vector)], and incubated with DMEM medium without FCS. PD98059 (100 mM; MKK1 inhibitor)
was added just after the transfection of MKK1(S222E).Whole cell lysates were separated by SDS-PAGE gels. Cyclin D1 protein levels were
detected by Western blot analysis. Luciferase enzyme units were normalized to b-galactosidase. The N-fold increase in luciferase activity was
calculated relative to the basal level of luciferase activity transfected with the empty vector. Results are means 6 sem of four or five independent
experiments (*P , 0.05; #P , 0.01). (D) Whole cell lysates were separated by SDS-PAGE gels. The cyclin D1 protein levels were detected by
Western blot analysis. For the detection of cyclin D1 the primary antibodies (diluted 1/2500) and a second antibody, HRP-conjugated goat antirabbit
IgG (diluted 1/2500), were used. The bands were visualized by the Amersham ECL system with 5 to 10 minutes of exposure after extensive
washing of the membranes. Values were obtained by densitometry of immunoblots of cyclin cyclin D1, and expression is presented as fraction of
expression in control (pNK11). Results are means 6 sem of four independent experiments (*P , 0.05).
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abolished the growth-inhibitory effects of TGF-b, as
shown in Figure 1A. However, TGF-b significantly in-
hibit [3H]-thymidine incorporation in the presence of
TAK1K63W thymidine incorporation. We suspect that
the TAK1 pathway partially mediates the growth-inhibi-
tory pathway of TGF-b, and that other pathways such
as Smad or cell cycle inhibitors (p15INK4, p27Kip1) may be
involved in the growth-inhibitory mechanisms of TGF-b.
Cyclins D1, D2, D3, E and A have been implicated
as regulators of growth during G1 or at the G1/S transi-
tion, and all have been found to be capable of activating
cyclin-dependent kinases that phosphorylate Rb [30, 31].Fig. 7. Effects of TAK1 pathway on cell cycle progression in LLC-
PK1 cells. LLC-PK1 cells expressing pNK11 (empty vector) or TAK1dN These G1/S phase cyclins have been reported to be up-
were incubated in DMEM medium with or without 10% FCS for 24 regulated in the pathogenesis of renal hypertrophy and
hours. The percentages of S phase and G2/M phase were analyzed by
acute renal failure [32–34]. A clear understanding of theflow cytometry using a FACS flow cytometer. Cell cycle analyses by
flow cytometry were performed for four times. regulatory mechanism of these genes is important for
further interpretation of these pathological states.
As a regulatory component of CDK2 and CDC2 ki-
nases, cyclin A plays an essential role in the progression
pression of constitutive negative mutants of MKK6 and through the S phase of the cell division cycle [30, 31].
p38K or SB203580. Its mRNA and protein start accumulating at the end of
We observed that MKK3/6 and p38K are phosphory- the G1 phase, and microinjection of antibodies directed
lated by overexpression of TAK1 to the same extent that at cyclin A or antisense cyclin A expression vectors pre-
they are by overexpression of TAK1dN (Fig. 3A). On vents DNA replication [35]. Statterwhite et al reported
the other hand, the wild type TAK1 did not show a that TGF-b inhibited mRNA expression of cyclin A and
significant inhibitory effect on the [3H]-thymidine uptake B-myb in mouse keratinocyte and Mv1Lu cells [36].
(Fig. 1). Although we do not have a clear solution to However, they did not examine the signal transduction
this discrepancy, there are some possible explanations. mechanisms of the inhibitory effects of TGF-b on cyclin
One observation from the lower panel of Figure 3A A expression [36]. Here, to our knowledge for the first
is that the inhibition of cyclin D1 protein expression by time, we demonstrate that cyclin A promoter activity
overexpression of TAK1 is very slight compared to the is down-regulated by the TAK1-MKK6-p38K pathway.
inhibition by the overexpression of TAK1dN. We also The downstream signaling of p38K to cyclin A promoter
observed that TAK1 slightly inhibited cyclin D1 pro- is not clarified in our present study. We know that one
moter activity, but not to a statistically significant extent of the possible transcription factors involved in this path-
(Fig. 3B). In Figure 4A, the inhibition of cyclin A pro- way is ATF2, a reported substrate of p38K, since the
moter activity and protein expression by TAK1 was only ATF site is reported in the promoter sequence of human
slight compared to the inhibition by TAK1dN. These cyclin A promoter [25].
results suggested that the weak affect of TAK1 on [3H]- In a study by Sylvester et al, Ras-dependent mitogenic
thymidine uptake might be explained by the weak inhibi- signaling was reported to be essential for the normal
tion of cyclin D1 and cyclin A promoter activities and stimulation of cyclin A promoter activity and DNA syn-
protein expressions by TAK1 in comparison to the inhi- thesis in vascular smooth muscle cells (VSMCs) [37].
bition by TAK1dN. They reported that AP-1 transcription factor c-fos medi-
It is not clearly known why TAK1 did not inhibit cyclin ated this requirement via interaction with the cAMP-
D1 and cyclin A promoter activities at levels similar to responsive element (CRE) in the cyclin A promoter. Our
TAK1dN. Since we did not observe time course activa- finding that cyclin A promoter activity was stimulated
tion of MKK3/6 and p38K in Figure 3A, one explanation by MKK1-p42/44MAPK concords with these previous
might be that the duration of kinase activation is longer reports. Ras-dependent mitogenic signaling could stimu-
in the TAK1dN. There is also some possibility that late the MKK1-p42/44MAPK pathway and then phos-
TAK1dN exhibits prolonged activation of MKK3/6 and phorylate c-fos and activate cyclin A promoter in LLC-
p38K compared to TAK1 since it has a constitutive active PK1 cells.
form of the kinase domain. On this basis, we surmised The D-type cyclins appear to reach maximal expres-
that the activated TAK1-MKK3/5-p38K pathway inhib- sion during early to mid-G1 in response to mitogenic
ited cyclin D1 and cyclin A transcription and cell cycle stimulation [38]. Ko et al have described TGF-b as a
progression in LLC-PK1 cells. negative regulatory factor that inhibits cyclin D1 expres-
sion transcriptionally in intestinal epithelial cells [39].Transfection of TAK1K63W plasmid significantly
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